- Douglas R Galasko, University of California, San Diego
- Todd E Golde, University of Florida
- Philip Scheltens, VU University Medical Center
Affiliated to Alzheimer's Disease International (ADI), London, United Kingdom
Alzheimer's Disease International is the international federation of national Alzheimer organisations and global voice for dementia, leading and unifying the dementia community to provide global solutions to a global epidemic.
A pattern separation test in mild to moderate Alzheimer’s disease patients suggests a possible genetic link to poor hippocampal neurogenesis, with performance related to apolipoprotein ϵ4 status and cerebrospinal fluid amyloid-β42 levels.
Transmembrane glycoprotein TMEM106B is downregulated, and progranulin is upregulated, in Alzheimer’s disease (AD) brains compared to non-AD brains, suggesting TMEM106B may have a key role in AD pathogenesis.
Lannfelt and colleagues review previous and ongoing active and passive amyloid-beta immunotherapy programs at the clinical stage, discussing why BAN2401 is a promising therapeutic candidate in early Alzheimer’s disease and hopes for other new innovative therapies.
Pharmacological manipulation of neurons in vitro by platelet-activating factor (PAF) antagonists significantly increases amyloid-beta42 degradation, supporting that PAF controls a cholesterol-sensitive pathway that affects the cellular localisation and fate of amyloid-beta42.
Based on genetic, risk factor, clinical and preclinical studies, Toyn and Ahlijanian propose clinical trials need to lower amyloid-beta (Aβ) by a minimum of 25% to adequately test the amyloid hypothesis in Alzheimer's disease.
Siddique and colleagues review the ubiquitin-proteasome or autophagy pathways whose dysfunction might contribute to the pathology of various neurodegenerative diseases, discussing how induction of these pathways may be a therapeutic strategy.
A care coordination programme between community and health organisations for patients with Alzheimer's disease and their carers resulted in improvements in psychosocial function of people with dementia.
Histone deacetylase 6 (HDAC6) inhibition by tubastatin A improved memory and reduced total tau levels in a mouse model of tau deposition; supporting HDAC6 inhibitors as novel therapeutic agents against tau pathology.
Latest free review
The following review has recently become free to access:
Nicole J Ridley, Brian Draper, Adrienne WithallAlzheimer's Research & Therapy 2013, 5:3 (25 January 2013)
From the blog
Aims & scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports. Although the primary focus is Alzheimer's dementia, the scope encompasses translational research into other neurodegenerative diseases.
The evolving field of traumatic brain injury
What do we currently know about chronic traumatic encephalopathy (CTE) and what are the most important questions in the field? Listen to a free podcast discussing this and more, as part of our special series on Traumatic Brain Injury.
Searching for biomarkers
As part of our special series on Peripheral Biomarkers, listen to a free podcast by Douglas Galasko about the advances and current issues in the search to identify blood biomarkers for Alzheimer's disease.